Mersana TherapeuticsMRSN
MRSN
0
Funds holding %
of 7,390 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
150% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 12
13% more funds holding
Funds holding: 116 [Q3] → 131 (+15) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]
12.99% less ownership
Funds ownership: 97.5% [Q3] → 84.5% (-12.99%) [Q4]
24% less repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 42
34% less capital invested
Capital invested by funds: $226M [Q3] → $149M (-$76.9M) [Q4]
82% less call options, than puts
Call options by funds: $356K | Put options by funds: $2.03M
Research analyst outlook
We haven’t received any recent analyst ratings for MRSN.
Financial journalist opinion
Based on 5 articles about MRSN published over the past 30 days
Neutral
Seeking Alpha
2 weeks ago
Mersana Therapeutics, Inc. (MRSN) Q4 2024 Earnings Call Transcript
Mersana Therapeutics, Inc. (MRSN) Q4 2024 Earnings Call Transcript

Negative
Zacks Investment Research
2 weeks ago
Mersana Therapeutics, Inc. (MRSN) Reports Q4 Loss, Tops Revenue Estimates
Mersana Therapeutics, Inc. (MRSN) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.16 per share a year ago.

Neutral
GlobeNewsWire
2 weeks ago
Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2024 Financial Results
CAMBRIDGE, Mass., March 03, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2024.

Neutral
GlobeNewsWire
3 weeks ago
Mersana Therapeutics to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will participate in the following upcoming investor events:

Neutral
GlobeNewsWire
3 weeks ago
Mersana Therapeutics to Host Fourth Quarter and Year End 2024 Conference Call on March 3, 2025
CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report its financial results for the fourth quarter and full year ended December 31, 2024 on Monday, March 3, 2025. The company will host a conference call and webcast at 8:00 a.m. Eastern Time that morning.

Neutral
GlobeNewsWire
1 month ago
Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that on February 3, 2025, the Compensation Committee of the Board of Directors of Mersana granted an inducement award, consisting of a restricted stock unit (RSU) award to acquire 20,610 shares of its common stock, to one new employee whose employment commenced in January 2025. The award was granted as an inducement material to the new employee entering employment with Mersana in accordance with Nasdaq Listing Rule 5635(c)(4).

Neutral
GlobeNewsWire
1 month ago
Mersana Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference
CAMBRIDGE, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that members of management will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on February 6, 2025 at 1:30 p.m. ET. A live webcast of this event will be available on the Investors & Media section of Mersana's website at www.mersana.com, and an archived replay will be available for approximately 90 days following the event.

Neutral
Benzinga
2 months ago
Why Is Cancer-Focused Mersana Therapeutics Stock Trading Lower On Friday?
On Friday, Mersana Therapeutics Inc. MRSN released initial data from the Phase 1 dose escalation and backfill cohorts for emiltatug ledadotin.

Neutral
GlobeNewsWire
2 months ago
Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)
Conference call to discuss positive initial Phase 1 clinical data today at 8:30 a.m. ET Conference call to discuss positive initial Phase 1 clinical data today at 8:30 a.m. ET

Neutral
GlobeNewsWire
2 months ago
Mersana Therapeutics Announces Positive Initial Clinical Data from Phase 1 Clinical Trial of Emiltatug Ledadotin (XMT-1660); Initiation of Expansion in Triple Negative Breast Cancer
- Emiltatug ledadotin observed to be generally well tolerated with differentiated safety and tolerability profile - Promising clinical activity observed in patients with triple-negative breast cancer (TNBC) previously treated with topoisomerase-1 inhibitor (topo-1) ADCs; confirmed responses observed across all enrolled tumor types - First expansion cohort initiated in patients with TNBC previously treated with at least one topo-1 ADC; dose exploration efforts ongoing - Company announces expected 2025 milestones and areas of focus - Conference call today at 8:30 a.m. ET

Charts implemented using Lightweight Charts™